[Lipoprotein (a) and plasminogen in atherosclerosis]

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Clinical Pathology

Background:

• Atherosclerotic disease is a major global health concern.
• Lipoprotein (a) [LP(a)] and plasminogen are key factors in vascular health and thrombosis.
• Understanding their interplay in atherosclerosis is crucial for risk assessment.

Purpose of the Study:

• To evaluate plasma levels of LP(a) and plasminogen in patients with atherosclerosis.
• To investigate the relationship between LP(a) and plasminogen in different atherosclerotic conditions.
• To explore correlations with patient age, lesion burden, and disease severity.

Main Methods:

• Plasma samples were collected from 84 patients with various forms of atherosclerosis (peripheral arteriopathy, ischemic heart disease, multi-infarct dementia) and 20 healthy controls.
• LP(a) and plasminogen levels were quantified.
• Statistical analysis was performed to assess correlations and group differences.

Main Results:

• Atherosclerotic patients exhibited significantly higher LP(a) levels (>30 mg/dl) compared to controls.
• Plasminogen levels were lower (<80 mg/dl) in atherosclerotic patients.
• An inverse correlation was observed between LP(a) and plasminogen levels.
• LP(a) and plasminogen levels showed differential behavior related to patient age, number of atherosclerotic lesions, and ischemic heart disease acuteness.

Conclusions:

• Elevated LP(a) and reduced plasminogen are characteristic of atherosclerotic disease.
• The inverse relationship between LP(a) and plasminogen suggests a complex pathophysiological link.
• These markers may serve as indicators for atherosclerotic disease progression and severity.